Cumulative Tenofovir Exposure Among Patients With HIV/Hepatitis B Coinfection With Differential Viral Suppression

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 May 4

PMID 38703389

Authors

Helen L Zhang

Meredith Mock

Lane Bushman

Peter L Anderson

Jennifer J Kiser

Susanna Naggie

Affiliations

Soon will be listed here.

Abstract

This case-control study explored cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatis B virus (HIV/HBV) coinfection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n = 4) compared to those with complete suppression (n = 5) (516 vs 1456 fmol/punch).

Citing Articles

Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV/HIV coinfection.

Ryan P, Odegard E, Meeds H, Lartey M, Ganu V, Tachi K J Clin Virol. 2024; 175:105733.

PMID: 39413542 PMC: 11781354. DOI: 10.1016/j.jcv.2024.105733.

References

Castillo-Mancilla J, Zheng J, Rower J, Meditz A, Gardner E, Predhomme J . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012; 29(2):384-90. PMC: 3552442. DOI: 10.1089/AID.2012.0089. View

Anderson P, Liu A, Castillo-Mancilla J, Gardner E, Seifert S, McHugh C . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740314. DOI: 10.1128/AAC.01710-17. View

Calcagno A, Gonzalez de Requena D, Simiele M, DAvolio A, Tettoni M, Salassa B . Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother. 2013; 57(4):1840-3. PMC: 3623307. DOI: 10.1128/AAC.02434-12. View

Kim H, Newcomb C, Carbonari D, Roy J, Torgersen J, Althoff K . Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology. 2021; 74(3):1190-1202. PMC: 8843101. DOI: 10.1002/hep.31839. View

Wong T, Lan A, Kiser J, Anderson P, Patel K, Tillman H . Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. Hepatology. 2016; 64(3):999-1000. PMC: 4956582. DOI: 10.1002/hep.28461. View

Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard P . Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology. 2014; 60(2):497-507. DOI: 10.1002/hep.27182. View

Thio C . Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009; 49(5 Suppl):S138-45. DOI: 10.1002/hep.22883. View

Zheng J, Guida L, Rower C, Castillo-Mancilla J, Meditz A, Klein B . Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2013; 88:144-51. PMC: 3842403. DOI: 10.1016/j.jpba.2013.08.033. View

Hafkin J, Osborn M, Localio A, Amorosa V, Kostman J, Stern J . Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat. 2014; 21(4):288-96. PMC: 3950944. DOI: 10.1111/jvh.12142. View

10.

Matthews G, Seaberg E, Avihingsanon A, Bowden S, Dore G, Lewin S . Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013; 56(9):e87-94. PMC: 3693490. DOI: 10.1093/cid/cit002. View

11.

Yager J, Castillo-Mancilla J, Ibrahim M, Brooks K, McHugh C, Morrow M . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. J Acquir Immune Defic Syndr. 2020; 84(3):323-330. DOI: 10.1097/QAI.0000000000002354. View

12.

Luetkemeyer A, Charlebois E, Hare C, Black D, Smith A, Havlir D . Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. J Acquir Immune Defic Syndr. 2011; 58(3):e96-9. PMC: 4120944. DOI: 10.1097/QAI.0b013e3182303937. View

13.

Puoti M, Torti C, Bruno R, Filice G, Carosi G . Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2005; 44(1 Suppl):S65-70. DOI: 10.1016/j.jhep.2005.11.015. View

14.

Hofmann E, Surial B, Boillat-Blanco N, Gunthard H, Stockle M, Bernasconi E . Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection. Clin Infect Dis. 2022; 76(4):730-733. DOI: 10.1093/cid/ciac823. View

15.

Cho W, Lee H, Bang K, Kim S, Song I . Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. World J Gastroenterol. 2018; 24(17):1919-1924. PMC: 5937209. DOI: 10.3748/wjg.v24.i17.1919. View